Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy

• Published in: Investigative ophthalmology & visual science 2023-10, Vol.64 (13), p.35-35
• Main Authors: Kim, Viktoria, Guberina, Maja, Bechrakis, Nikolaos E., Lohmann, Dietmar R., Zeschnigk, Michael, Le Guin, Claudia H. D.
• Format: Article
• Language: English
• Subjects: Anatomy and Pathology/Oncology
• ISSN: 1552-5783; 0146-0404; 1552-5783
• DOI: 10.1167/iovs.64.13.35

PurposeUveal melanoma (UM) is a tumor of the eye that metastasizes in approximately half of cases. Prognostic testing requires accessibility to tumor tissue, which is usually not available with eye-preserving therapies. Noninvasive approaches to prognostic testing that provide valuable information for patient care are therefore needed. The aim of this study was to evaluate the use of circulating cell-free plasma DNA analysis in UM patients undergoing brachytherapy.MethodsThe study recruited 26 uveal melanoma patients referred to the department between February and October 2020. Blood samples were collected at various time points before, during, and after treatment, and deep amplicon sequencing was used to identify oncogenic variant alleles of the GNAQ and GNA11 genes, which serve as indicators for the presence of circulating tumor DNA (ctDNA).ResultsThe results showed that all patients were ctDNA negative before brachytherapy. In 31% of patients, ctDNA was detected during therapy. The variant allele fraction of GNAQ or GNA11 alleles in ctDNA positive samples ranged from 0.24% to 2% and correlates with the largest basal diameter and thickness of the tumor.ConclusionsThe findings suggest that brachytherapy increases the presence of tumor DNA in the plasma of UM patients. Thus ctDNA analysis may offer a noninvasive approach for prognostic testing. However, efforts are still required to lower the limit of detection for tumor-specific genetic alterations.